These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16158214)

  • 1. Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: an integrated parent-metabolite model.
    Ortega F; Quintana A; Suárez E; Lukas JC; Jauregizar N; de la Fuente L; Lucero ML; Gonzalo A; Orjales A; Calvo R
    Pharm Res; 2005 Nov; 22(11):1769-82. PubMed ID: 16158214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacological effect of lerisetron, a new 5-HT3 antagonist, in rats.
    Jauregizar N; Calvo R; Suarez E; Quintana A; Raczka E; Lukas JC
    J Pharm Sci; 2002 Jan; 91(1):41-52. PubMed ID: 11782896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered disposition and effect of lerisetron in rats with elevated alpha 1-acid glycoprotein levels.
    Jauregizar N; Calvo R; Suarez E; Quintana A; Raczka E; Lukas JC
    Pharm Res; 2001 Jun; 18(6):838-45. PubMed ID: 11474789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related changes in pharmacokinetics and pharmacodynamics of lerisetron in the rat: a population pharmacokinetic model.
    Jauregizar N; Quintana A; Suarez E; Raczka E; de la Fuente L; Calvo R
    Gerontology; 2003; 49(4):205-14. PubMed ID: 12792155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer.
    Calvo R; Jiménez RM; Trocóniz IF; Suárez E; Gonzalo A; Lucero ML; Raczka E; Orjales A
    Cancer Chemother Pharmacol; 1998; 42(5):418-22. PubMed ID: 9771958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers.
    Cooper M; Sologuren A; Valiente R; Smith J
    Arzneimittelforschung; 2002; 52(9):689-94. PubMed ID: 12404884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response.
    Bundgaard C; Larsen F; Kreilgaard M; Brennum LT; Olsen CK
    Biopharm Drug Dispos; 2009 May; 30(4):209-20. PubMed ID: 19475539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as "bath salts".
    López-Arnau R; Martínez-Clemente J; Carbó Ml; Pubill D; Escubedo E; Camarasa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():64-72. PubMed ID: 23603357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional group interactions of a 5-HT3R antagonist.
    Venkataraman P; Joshi P; Venkatachalan SP; Muthalagi M; Parihar HS; Kirschbaum KS; Schulte MK
    BMC Biochem; 2002 Jun; 3():16. PubMed ID: 12079499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: a microdialysis study.
    Bertera FM; Mayer MA; Opezzo JA; Taira CA; Bramuglia GF; Höcht C
    J Pharmacol Toxicol Methods; 2007; 56(3):290-9. PubMed ID: 17560132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
    Miyazaki M; Maekawa C; Iwanaga K; Morimoto K; Kakemi M
    Biol Pharm Bull; 2000 Nov; 23(11):1363-9. PubMed ID: 11085367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach.
    Rodriguez M; Carlos MA; Ortega I; Suarez E; Calvo R; Lukas JC
    Pharm Res; 2002 Jun; 19(6):858-67. PubMed ID: 12134958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension.
    Bertera FM; Mayer MA; Opezzo JA; Taira CA; Höcht C
    J Pharmacol Toxicol Methods; 2008; 57(3):212-9. PubMed ID: 18442930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.
    Shang GW; Liu DN; Yan LH; Cui XY; Zhang KP; Qi C; Chen J
    Pharmacol Biochem Behav; 2006 Oct; 85(2):464-73. PubMed ID: 17126387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic modeling of telmisartan using an indirect response model in spontaneously hypertensive rats.
    Hao K; Chen YC; Cao YG; Yu D; Liu XQ; Wang GJ
    Acta Pharmacol Sin; 2007 May; 28(5):738-43. PubMed ID: 17439731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats.
    Yassen A; Kan J; Olofsen E; Suidgeest E; Dahan A; Danhof M
    J Pharmacol Exp Ther; 2007 May; 321(2):598-607. PubMed ID: 17283225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
    Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study.
    Park SM; Lee J; Seong SJ; Park JG; Gwon MR; Lim MS; Lee HW; Yoon YR; Yang DH; Kwon KI; Han S
    BMC Pharmacol Toxicol; 2014 Dec; 15():75. PubMed ID: 25534747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.
    Kumar Puttrevu S; Ramakrishna R; Bhateria M; Jain M; Hanif K; Bhatta RS
    Naunyn Schmiedebergs Arch Pharmacol; 2017 May; 390(5):457-470. PubMed ID: 28190245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.